RITUXIMAB AND SARGRAMOSTIM IMMUNOTHERAPY FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANT FOR AGGRESSIVE NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Scigliano, E. [1 ]
Grosskreutz, C. L. [1 ]
Osman, K. [1 ]
Malone, A. [1 ]
Nieto, J. [1 ]
Isola, L. M. [1 ]
机构：
[1] Mt Sinai Med Ctr, New York, NY 10029 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2009.12.167
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
136
引用
收藏
页码：S208 / S209
页数：3
相关论文
共 50 条
  • [41] Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma
    Holmberg, Leona A.
    Maloney, David
    Bensinger, William
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 135 - 139
  • [42] Clinical factors influencing engraftment in patients with non-Hodgkin lymphoma following autologous stem cell transplant.
    Skelton, William Paul
    Lutfi, Forat
    Wang, Yu
    Rosenau, Emma
    Murthy, Hemant S.
    Brown, Randy
    Wingard, John R.
    Norkin, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Single or double autologous stem cell transplantation for transformed aggressive B-cell non-Hodgkin's lymphoma
    Clavert, A.
    Roland, V.
    Le Gouill, S.
    Dubruille, V.
    Mahe, B.
    Gastinne, T.
    Blin, N.
    Chevallier, P.
    Guillaume, T.
    Delaunay, J.
    Ayari, S.
    Devys, A.
    Flandrois, G.
    Saulquin, B.
    Moreau, A.
    Moreau, P.
    Harousseau, J. L.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S211 - S211
  • [44] The role of salvage therapy post autologous stem cell transplantation in aggressive non-Hodgkin's lymphoma.
    Yano, S
    Sekiguchi, N
    Asai, O
    Dobashi, N
    Sugiyama, K
    Saito, T
    Yahagi, Y
    Osawa, H
    Okawa, Y
    Kasama, K
    Hisatomi, M
    Ueda, K
    Hoshi, Y
    Usui, N
    Kobayashi, M
    BLOOD, 2003, 102 (11) : 483B - 483B
  • [45] High-dose therapy with autologous stem-cell transplantation in aggressive non-Hodgkin's lymphoma
    Verdonck, LF
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 3003 - 3003
  • [46] Is Rituximab Needed With High Dose Chemotherapy and Autologous Stem Cell Transplant When Patients With Non-Hodgkin's Lymphoma Have Been Exposed To It?
    Gul, Zartash
    Anderson, Stephan
    Slone, Stacey
    Chhabra, Saurabh
    Monohan, Gregory
    Howard, Dianna
    Lawson, Amber
    Hayslip, John
    BLOOD, 2013, 122 (21)
  • [47] High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
    Blaker, Yngvild N.
    Eide, Marianne B.
    Liestol, Knut
    Lauritzsen, Grete F.
    Kolstad, Arne
    Fossa, Alexander
    Smeland, Erlend B.
    Holte, Harald
    LEUKEMIA & LYMPHOMA, 2014, 55 (10) : 2319 - 2327
  • [48] IMMUNOTHERAPY WITH RITUXIMAB (RITUXAN)/INTERLEUKIN 2 (IL-2) FOLLOWING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (ASCT) AS TREATMENT FOR CD20 POSITIVE NON-HODGKIN'S LYMPHOMA
    Holmberg, L. A.
    Maloney, D. G.
    Bensinger, W., I
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 39 - 39
  • [49] Evans' syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
    Kamezaki, K
    Fukuda, T
    Makino, S
    Harada, M
    CLINICAL AND LABORATORY HAEMATOLOGY, 2004, 26 (04): : 291 - 293
  • [50] Autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
    Salles, G
    Coiffier, B
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 1999, 12 (1-2) : 151 - 169
12345